Lommatzsch Marek
Abteilung für Pneumologie/Interdisziplinäre Internistische Intensivstation, Medizinische Klinik I, Zentrum für Innere Medizin, Universitätsmedizin Rostock.
Dtsch Med Wochenschr. 2020 Jun;145(11):767-771. doi: 10.1055/a-1003-7142. Epub 2020 Jun 3.
Accumulating evidence suggests that a symptom-driven therapy with fixed combinations of inhaled corticosteroids (ICS) and formoterol is safer and more feasible in patients with mild asthma than a treatment with short-acting beta-2-agonists (SABA) alone. Therefore, the new international GINA asthma guideline (2019) recommends, for the first time, as needed low dose ICS-formoterol as the preferred controller in treatment step 1. This radical paradigm shift will have a major impact on asthma care in the future.
越来越多的证据表明，对于轻度哮喘患者，吸入性糖皮质激素（ICS）和福莫特罗固定复方制剂的症状驱动疗法比单独使用短效β2激动剂（SABA）治疗更安全、更可行。因此，新的国际全球哮喘防治创议（GINA）哮喘指南（2019年）首次推荐，按需使用低剂量ICS-福莫特罗作为治疗第1步的首选控制药物。这一根本性的范式转变将对未来的哮喘治疗产生重大影响。
